Skip to content

Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02025023
Acronym
CTS
Enrollment
120
Registered
2013-12-31
Start date
2013-12-31
Completion date
2026-07-31
Last updated
2020-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chalazion

Keywords

Size, Pain, Resolution, Complications, Swelling

Brief summary

Local injection of 5-fluorouracil into a chalazion (stye) is as effective as local injection of triamcinolone (steroid) and incision and curettage for treatment of chalazia.

Detailed description

This is a prospective randomized interventional study comparing four current standard-of-care treatments for chalazia: incision and curettage, local injection of triamcinolone, local injection of 5-FU, and local injection of combination triamcinolone/5-FU.

Interventions

If the chalazion is present at follow-up visit, another injection of 5-FU will be given.

DRUGTriamcinolone Acetonide

If chalazion present at follow-up, another Triamcinolone injection will be done.

PROCEDUREIncision and Curettage

If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.

DRUGTriamcinolone Acetonide/5-fluorouracil mixture

If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.

Sponsors

University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Single or multiple chalazia in a single eyelid

Exclusion criteria

* Chalazia present for less than one month and no previous injection or incision and curettage

Design outcomes

Primary

MeasureTime frame
Size of chalazion4 weeks

Countries

United States

Contacts

Primary ContactSimona Vuletic
simona@uw.edu206-520-9728
Backup ContactIan Luttrell
lutri@uw.edu206-520-8305

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026